Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis
Authors' conclusion
In this registry study, CP showed no survival benefit in ATC; outcomes depended on disease burden and resectability
Study context
- Population
- Adults with histologically confirmed anaplastic thyroid cancer (ATC) treated with first-line cytotoxic chemotherapy at 7 German tertiary centres (2000–2024)
- Participants
- 158 adults
- Exposure
- First-line carboplatin/paclitaxel (CP) ± radiotherapy vs other cytotoxic chemotherapy regimens
- CPn = 97
- Other chemotherapyn = 61reference
- Outcome
- PFS and OS
Main finding
As reported in the abstract
Progression-free survival (PFS)
102 vs 89 days
log-rank P = .23
CP
Overall survival (OS)
278 vs 295 days
P = 0.50
CP
Observational data: associations, not effects.
Further findings
Complete response
P = 0.46
Mortality risk factors (multivariable Cox analysis)
- Age ≥65 years, lymph node metastasis and distant metastasis associated with higher mortality risk
- Surgery associated with lower mortality risk
- CP not associated with improved OS
Second-line treatment outcome
- Outcome not different for chemotherapy vs kinase inhibition ± immunotherapy
Original publication
Outcome of first-line chemotherapy for anaplastic thyroid cancer—a multicenter registry analysis. J Clin Endocrinol Metab. Published 21 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →